| Autor: |
Tingting Sun, Mamie Z. Li, Earlene M. Schmitt, Zachary C. Hartman, Peng Yu, Nicole L. Solimini, Bing Yu, Rachel Schiff, Stephen J. Elledge, Rocio Dominguez-Vidana, Tiffany Y.T. Hsu, Ido Golding, Ji Luo, Jessica D. Kessler, Anthony C. Liang, Chad A. Shaw, Michael R. Schlabach, Kristen L. Meerbrey, Kristopher T. Kahle, Thomas F. Westbrook, C. Kent Osborne, Susan G. Hilsenbeck, Ronald J. Bernardi, Samuel O. Skinner, Mitchell Rao, Chad J. Creighton, Qikai Xu |
| Rok vydání: |
2011 |
| Předmět: |
|
| Zdroj: |
Science (New York, N.Y.). 335(6066) |
| ISSN: |
1095-9203 |
| Popis: |
Taking the Myc Despite nearly 30 years of research into the mechanisms by which Myc oncogene dysregulation contributes to tumorigenesis, there are still no effective therapies that inhibit Myc activity. Kessler et al. (p. 348 , published online 8 December; see the Perspective by Evan ) searched for gene products that support Myc-driven tumorigenesis. One pharmacologically tractable target that emerged from the screen was the SUMO-activating enzyme complex SAE1/2, which catalyzes a posttranslational modification (SUMOylation) that alters protein behavior and function. SUMOylation was found to control the Myc transcriptional response, and its inhibition caused mitotic defects and apoptosis in Myc-dependent breast cancer cells. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
